CIBC Has Lowered Expectations for DRI Healthcare Trust (TSE:DHT.UN) Stock Price

DRI Healthcare Trust (TSE:DHT.UN) had its price target lowered by investment analysts at CIBC from C$19.50 to C$18.00 in a report issued on Thursday,BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. CIBC’s price objective suggests a potential upside of 48.03% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Raymond James reduced their price target on DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th. Scotiabank upped their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of C$17.94.

DRI Healthcare Trust Price Performance

DHT.UN stock opened at C$12.16 on Thursday. DRI Healthcare Trust has a fifty-two week low of C$10.39 and a fifty-two week high of C$17.43. The business’s 50-day moving average is C$13.35 and its two-hundred day moving average is C$13.22.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.